SGLT2 Inhibitors: Unreal Primary Prevention? | Latest News RSS feed

SGLT2 Inhibitors: Unreal Primary Prevention? - Latest News


It's Personal: EASD Focuses on Individualizing Diabetes Care

with some arguing that the purported findings of a primary prevention benefit for SGLT2 inhibitors — that they protect against cardiovascular death in patients with type 2 diabetes with no history of ... read more

New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with ...

The primary endpoint was defined as time to ... highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk ... read more

Panel Meeting For Victoza And Decision Time For Portola's Anticoagulant

In its outcomes trial, Leader, Victoza's benefit was largely down to prevention of cardiovascular death ... Competition from the SGLT2 inhibitor class is likely to become even stiffer - Lilly and Boeh... read more

Looking for another news?


Study reveals sotagliflozin in conjunction with insulin reduces average blood glucose levels

the ADA's peer-reviewed research journal dedicated to diabetes treatment and prevention. Sotagliflozin is an investigational dual inhibitor of sodium glucose transport proteins 1 and 2 (SGLT1 and SGLT... read more


Treating Diabetes in Patients With CKD at Kidney Week

BEST (NCT02558296) is evaluating the safety and effectiveness of bexagliflozin, a sodium glucose transporter 2 (SGLT2) inhibitor, in patients with type 2 diabetes and stage 3a/3b CKD. The primary end ... read more

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

"The AWARD-10 results suggest that the combination of once-weekly Trulicity and an SGLT-2 inhibitor shows significant promise in helping more people with type 2 diabetes reach their treatment goals." ... read more

New oral diabetes drugs may also protect patients' kidney health

"The apparent renal and cardiovascular benefits of SGLT2 inhibitors will encourage primary care physicians and endocrinologists to use these agents more frequently in the care of patients with type 2 ... read more

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes

1 Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 2 Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public ... read more

Boehringer Ingelheim, Lilly ink academic collaboration with University of Oxford to investigate effects of empagliflozin in people with CKD

The primary outcome of the study is to assess the effect of ... the largest clinical development programme of an SGLT2 inhibitor. “We are delighted to partner with such a prestigious academic institut... read more

Standards of Medical Care in Diabetes—2015 Abridged for Primary Care Providers

This is an abridged version of the current Standards containing only the evidence-based recommendations most pertinent to primary care. The tables, figures, and references have been renumbered from th... read more

Repatha's Next Challenge Is Expectations

Both will have much to prove, as payers are eager to see whether a profound reduction of LDL can translate into prevention of cardiovascular complications ... The anti-diabetic SGLT-2 drugs have earne... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us